Synonyms: AIN457
Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.
Shimon Sakaguchi
Nature Communications 2025;16, Article number:1325
David Baker
Dev Cell 2023;58(20):2163-2180.e9.
Michael Houghton
Cell Chem Biol 2020;27(7):780-792.e5
David Julius
Cell 2017;185-198.e16
Charles M. Rice
Cell 2018;172(3):423-438.e25
| Description |
Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.
|
|---|---|
| In vitro |
Secukinumab can reduce cell growth in the miR130b-knockdown OCI-ly10 co-culture system. |
| Cell Research |
MTT assay was adopted to measure cell growth in the control inhibitor or miR130b inhibitor transfected OCI-ly10 co-culture system upon treatment with or without IL17 inhibitor. |
| In vivo |
Secukinumab administration significantly attenuates AAV8-IRF8 mediated recruitment of neutrophils, also downregulates the autophagy level and inhibits the release of either autophagy-dependent or independent chemokines in vivo. |
| Animal Research |
Animal Models: C57BL/6 mice, IRF8 FLOX mice (C57BL/6J background) |
References |
|
| CAS No. | 1229022-83-6 |
|---|---|
| Isotype | Human IgG1 |
| Source | Human |
| Sterility | 0.2 μM filtered |
| Formulation | PBS buffer, pH 7.2 |
| Storage | Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.